Erschienen in:
21.03.2021 | ASO Author Reflections
ASO Author Reflections: Development and Validation of Distal Cholangiocarcinoma Early Recurrence (DICER) Score: Results from the US Extrahepatic Biliary Malignancy Consortium
verfasst von:
Kota Sahara, MD, Diamantis I. Tsilimigras, MD, Timothy M. Pawlik, MD, MPH, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Excerpt
Surgery remains the main curative-intent therapy for distal cholangiocarcinoma (DCC). Nevertheless, over half of patients with DCC will recur even after curative-intent resection. Despite the increasing use of adjuvant therapies (AT) for biliary tract cancers (BTCs),
1 the majority of patients with DCC will have early recurrence (ER) following resection, which is associated with a dismal prognosis.
2,
3 To this end, there is a need for better predictive tools to identify the subset of patients who are at particularly high risk of ER to help inform which individuals may benefit the most from early systemic therapy rather than upfront surgery. …